Novartis is opening a new manufacturing facility in California and expanding an existing production site in its bid to dominate the booming radiopharmaceuticals field amid burgeoning competition.
The pharmaceutical giant will spend more than $200 million to construct the new facility in Carlsbad, Calif., and expand its site in Indianapolis, representatives told STAT exclusively. The sites are expected to employ another 90 people and open by 2026.
Novartis is the leading producer of radiopharmaceutical or radioligand therapies, an emerging type of cancer treatment in which a potent dose of radioactive molecules is dispatched to harm cancer cells. This type of treatment has become a hot spot in drug development, leading to several acquisitions over the last year.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
